Recro Pharma Inc (REPH):企業の財務・戦略的SWOT分析

◆英語タイトル:Recro Pharma Inc (REPH) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH336048FSA
◆発行会社(調査会社):GlobalData
◆発行日:2020年12月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recro Pharma Inc (REPH) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recro Pharma Inc (Recro) provides contract development and manufacturing organization (CDMO) services. The company harnesses formulation capabilities and proprietary delivery technologies for the development, manufacture, and commercialization of pharmaceutical products of its partners. The company manufactures products such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR and Zohydro ER among others for its commercial partners. The company has a manufacturing facility in Gainesville, Georgia, the US. Recro Pharma is headquartered in Malvern, Pennsylvania, the US.

Recro Pharma Inc Key Recent Developments

Dec 16,2020: Recro announces executive changes
Aug 10,2020: Recro reports second quarter 2020 financial results
May 11,2020: Recro reports first quarter 2020 financial results and provides update on COVID-19 response and impact
Apr 07,2020: Recro Pharma receives loan under Paycheck Protection Program
Mar 04,2020: Recro reports financial results for the year ended 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recro Pharma Inc – Key Facts
Recro Pharma Inc – Key Employees
Recro Pharma Inc – Key Employee Biographies
Recro Pharma Inc – Major Products and Services
Recro Pharma Inc – History
Recro Pharma Inc – Company Statement
Recro Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recro Pharma Inc – Business Description
Recro Pharma Inc – Corporate Strategy
Recro Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Recro Pharma Inc – Strengths
Recro Pharma Inc – Weaknesses
Recro Pharma Inc – Opportunities
Recro Pharma Inc – Threats
Recro Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recro Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 16, 2020: Recro announces executive changes
Aug 10, 2020: Recro reports second quarter 2020 financial results
May 11, 2020: Recro reports first quarter 2020 financial results and provides update on COVID-19 response and impact
Apr 07, 2020: Recro Pharma receives loan under Paycheck Protection Program
Mar 04, 2020: Recro reports financial results for the year ended 2019
Nov 21, 2019: Recro completes separation of Baudax Bio and becomes a dedicated contract development and manufacturing organization
Nov 13, 2019: Recro Pharma announces effectiveness of Baudax Bio Form 10 Registration Statement
Nov 08, 2019: Recro Pharma reports third quarter 2019 financial results
Aug 08, 2019: Recro Pharma reports second quarter 2019 financial results
May 10, 2019: Recro Pharma reports first quarter 2019 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Recro Pharma Inc, Key Facts
Recro Pharma Inc, Key Employees
Recro Pharma Inc, Key Employee Biographies
Recro Pharma Inc, Major Products and Services
Recro Pharma Inc, History
Recro Pharma Inc, Subsidiaries
Recro Pharma Inc, Key Competitors
Recro Pharma Inc, Ratios based on current share price
Recro Pharma Inc, Annual Ratios
Recro Pharma Inc, Annual Ratios (Cont...1)
Recro Pharma Inc, Annual Ratios (Cont...2)
Recro Pharma Inc, Interim Ratios
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recro Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Recro Pharma Inc (REPH):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Diffusion Pharmaceuticals Inc (DFFN):企業の財務・戦略的SWOT分析
    Summary Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company that develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, includi …
  • Natural Alternatives International Inc (NAII):企業の財務・戦略的SWOT分析
    Summary Natural Alternatives International Inc (NAI) is a formulator and manufacturer of customized nutritional supplements. The company manufactures and distributes the only patented beta-alanine supplement on the market. It offers services such as science-based product formulation, raw material ac …
  • SmartCool Systems Inc (SSC):電力:M&Aディール及び事業提携情報
    Summary SmartCool Systems Inc (SmartCool Systems) is a clean technology company that manufactures and sells energy and cost reduction technologies. The company’s products include ECO3, ESM, and soft solutions. Its ECO3 and ESM are retrofit technologies that reduce the energy consumption of compresso …
  • MKB Private Banking:企業の戦略・SWOT・財務情報
    MKB Private Banking - Strategy, SWOT and Corporate Finance Report Summary MKB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Endeavour Mining Corporation:企業のM&A・事業提携・投資動向
    Endeavour Mining Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Endeavour Mining Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Enauta Participacoes SA (QGEP3):企業の財務・戦略的SWOT分析
    Summary Enauta Participacoes SA (Enauta), a subsidiary of Queiroz Galvao Group, is an oil and gas company that explores, develops and produces oil and gas properties. The company's exploration properties include Santos Basin, Espirito Santo Basin, Camamu-Almada Basin, Sergipe-Alagoas Basin, Pernambu …
  • H. Lee Moffitt Cancer Center & Research Institute Inc-医療機器分野:企業M&A・提携分析
    Summary H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider that concentrates on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services suc …
  • Nippon Chemi-Con Corporation (6997):企業の財務・戦略的SWOT分析
    Nippon Chemi-Con Corporation (6997) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Crane Co.:企業の戦略・SWOT・財務情報
    Crane Co. - Strategy, SWOT and Corporate Finance Report Summary Crane Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • PT Pembangkitan Jawa-Bali:電力:M&Aディール及び事業提携情報
    Summary PT Pembangkitan Jawa-Bali (PJB), a subsidiary of PT PLN (Persero), generates and supplies electricity. It is responsible to meet the electricity requirements of the Java-Madura-Bali (JAMALI) electric system. The company generates electricity from energy sources such as oil, natural gas, coal …
  • Ogeda SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ogeda SA (Ogeda), formerly Euroscreen SA, a subsidiary of Astellas Pharma Inc, is a clinical-stage drug discovery company that invents and develops fezolinetant and small molecule drugs targeting G-protein coupled receptors. The company discovers and develops drugs that treat hormone-depende …
  • Haplogen GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Haplogen GmbH (Haplogen) is a biopharmaceutical company that improves human health by fighting against infectious diseases such as common cold, dengue fever, influenza and hepatitis C. The company utilizes its proprietary genetics technology platform to identify novel pathogen host factors a …
  • Murata Manufacturing Co., Ltd.:企業の戦略・SWOT・財務分析
    Murata Manufacturing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murata Manufacturing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Temple Hotels Inc.
    Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report Summary Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Norgine BV:医療機器:M&Aディール及び事業提携情報
    Summary Norgine BV (Norgine) is a pharmaceutical company that offers medicinal products. The company develops drugs in the therapeutic areas of gastroenterology, incontinence, hepatology and critical and supportive care and pain management, among others. It offers the treatment of diseases related t …
  • MaxCyte Inc (MXCT):企業の財務・戦略的SWOT分析
    Summary MaxCyte Inc (MaxCyte) is a biotherapeutic company that conducts research and develops cell transfection technologies. The company offers MaxCyte STX, MaxCyte VLX and MaxCyte GT instruments. It utilizes flow electroporation technology for discovery, development and manufacturing of cell-based …
  • QAD Inc (QADA):企業の財務・戦略的SWOT分析
    QAD Inc (QADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Myriad Group AG:企業の戦略的SWOT分析
    Myriad Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Anixter International Inc.:企業の戦略・SWOT・財務情報
    Anixter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Anixter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆